解脲脲原体感染和不孕不育关系的研究

本文报道原因不明的不孕不育夫妇(甲组)2181例,解脲脲原体培养阳性1203例,阳性率55.16％。其中男性阳性率55.48％;女性为54.92％。正常生育夫妇(乙组)366例,阳性107例,阳性率为29.03％,其中男性18.93％,女性35.04％。两组比较,无论总阳性率,还是单独男性或女性,甲组均显著高于乙组(p<0.005)。经以强力霉素为主治疗后,转阴率达83.87％,其中妊娠390人,占38.65％。作者认为解脲脲原体感染和部分原因不明不孕不育是相关的。     

解脲脲原体生物膜药敏检测方法的研究进展

解脲脲原体（Uu）生物膜的培养及药敏检测技术是继支原体体外游离药敏试验之后,探讨Uu耐药水平与耐药机制的又一重要手段。然而由于支原体生长的生物学特性,使实验中需要多次更换培养基,增加了污染的概率。培养过程中的杂菌污染由此成为决定Uu生物膜实验成功与否的一大问题。本文将对解脲脲原体生物膜的培养与药敏检测技术,从检测方法、常见污染途径与解决策略3个方面展开,对相关文献作一综述。     

大学生尿沉渣中解脲脲原体和人型支原体感染情况分析

目的了解解脲脲原体(Ureaplasma urealytium,Uu)和人型支原体(Mycoplasma homanis,Mh)在大学生泌尿道中的感染情况.方法采用培养方法对37例正常的在校大学生的尿沉渣进行Uu和Mh的培养.结果采用培养方法检测21.6%(8/37)的大学生Uu感染为阳性,其中分离阳性者全部是女生(8/20,40%),13.50%(5/37)大学生Mh培养为阳性,其中阳性者亦全部为女生,占女生人数的25%(5/20).结论Uu和Mh可能是女性泌尿道的正常寄生的微生物之一.     

解脲脲原体耐药性研究进展

解脲脲原体是条件致病菌。目前对其耐药性的研究主要包括对喹诺酮类、大环内酯类和四环素类3种抗菌药物相关耐药突变位点的检测,以及生物膜对病原体相关药物敏感性的影响,研究方法和检验手段仍较为传统、局限,研究方案也仅停留在对前人实验的重复。近年来,有学者将多位点序列分型技术用于解脲脲原体耐药序列类型的研究。在完善耐药机制研究的基础上,如何实现对耐药株的快速鉴定,从而指导抗菌药物的合理选择等仍需进一步研究。     

解脲脲原体药物敏感性变迁研究

目的:探讨上海地区2008与2012年泌尿生殖道解脲脲原体(Ureaplasma urealyticum,UU)耐药性变化,为临床合理用药提供参考。方法:采用自制UU药物敏感检测试剂对2008年450例和2012年459例患者的标本进行检测,观察UU阳性情况及UU对交沙霉素、氧氟沙星、阿奇霉素和强力霉素的药物敏感性。结果:2008年分离到150例UU阳性标本和2012年分离到134例UU阳性标本分别对交沙霉素、强力霉素、氧氟沙星和阿奇霉素等4种抗菌素的敏感率有显著性差异;2008年46例和2012年38例男性患者阳性标本中分离的UU分别对交沙霉素和阿奇霉素敏感率有显著性差异;对强力霉素和氧氟沙星敏感率无显著性差异。2008年104例和2012年96例女性患者阳性标本中分离的UU分别对交沙霉素、强力霉素、氧氟沙星和阿奇霉素等4中抗菌素的敏感率都有显著性差异。结论:5年间UU药物敏感性发生了变迁;临床医师应该关注本地区药物敏感性变迁,合理选用抗生素。     

不孕不育患者解脲脲原体菌株血清型别的检测

本文以解脲脲原体标准菌株１－１４型免疫家获得ＵＵ１－１４型抗血清。用ＩＤＴ法对４８株自不孕不育患者分离的地方株作分型试验。结果在１．２．４．５．６．７．８和１２血八个清型中出现强阳性反应,其中４型最多。另有４株混合型。对四种血清型无反应。     

自然流产胚胎组织解脲脲原体检测分析

初步探讨解脲脲原体（Uu）感染与自然流产的相关性。对82例自然流产,44例人工流产（对照组）的胚胎组织进行Uu的人工分离培养,并对部分组织的超薄切片及培养物负染片置电镜下观察。结果显示,自然流产胚胎组织Uu的检出率为64．6％（53．82）,与对照组相比6．8％（3／44）,具有显著性差异（P＜0．001）;电镜下观察,Uu检出阳性标本中合体滋养细胞和细胞滋养细胞膜表面见大量的Uu颗粒,与阳性培养物经负染后了颗粒相似,而Uu阴性对照标本中未见此颗粒,提示：Uu可引起宫内感染,损伤绒毛膜滋养细胞,是导致自然流产的重要病原体之一。     

解脲脲原体感染与不孕不育

解脲脲原体是人类泌尿生殖道常见的寄生菌之一,它可以引起男女泌尿生殖道感染,其中最严重的后果认为可导致男女不孕不育。支原体感染是否与男性和女性的不孕不育有关,其致病的主要机制是什么,探讨这些问题对于防治解脲脲原体感染,减少及避免不孕不育疾病的发生有重要意义。本文对近年来关于解脲脲原体感染导致女性不孕和男性不育的机制进行了综合概述。     

Serological evidence of Ureaplasma urealyticum infection in neonatal respiratory disease

Since up to 80 percent of pregnant women and 30 percent of neonates may be colonized with genital mycoplasmas, it is difficult to determine whether true infection occurs. The antibody responses to eight serotypes of U. urealyticum were assessed in mothers and infants in 21 cases of neonatal respiratory disease (RD) and 24 normal cases. Among the normal population of mothers and infants, a titer of greater than or equal to 1:32 occurred in 0.25 percent (1/394). In mother-infant paired titers, a fourfold difference occurred in 2.6 percent (5/192). Among 54 RD neonates, 55.6 percent had a titer of greater than or equal to 1:32 compared to only 4.2 percent of normal neonates (p less than .001). Fourfold elevations in antibody titers of greater than 1:32 were observed in the neonate in 52.4 percent of RD cases compared to 0 percent of 24 normal pairs (p less than .001) and in 28.6 percent of mothers of RD neonates compared to 0 percent in normal cases (p = .013). We observed that 43.3 percent of RD neonates with titers greater than or equal to 1:32 died compared to 16.6 percent of RD neonates exhibiting no elevation of antibody response over the maternal level. Among the six who died, 66.7 percent of neonates and 16.7 percent of their mothers had elevated titers, compared to 33.3 percent of 15 surviving infants and 40.0 percent of their mothers. These elevated antibody responses strongly support the concept that U. urealyticum causes infection in the perinatal period in association with neonatal respiratory disease. Since the elevation in titers was detected close to delivery in many cases, the infection may occur in utero.     

The infection of monkeys with Ureaplasma urealyticum serovar VIII

The possibility of modeling chronic infection on monkeys by the injection of the culture of U. urealyticum, serotype VIII, was shown. The infection of monkeys with these microorganisms introduced in a single intraperitoneal injection resulted in the generalization of the process, which was manifested by the persistence and reproduction of the infective agent in the organs and blood of the animals for as long as 6 months (the term of observation). Lymphoid hyperplasia in the organs of immunogenesis and transitory immunomorphological reaction in the tissues of some organs of the urogenital system were noted. The localization of infective agents in some endocrine glands was not accompanied by disturbances in their function.     

Ureaplasma urealyticum and Ureaplasma parvum in etiology of urogenital mixt-infections

The complex study of 104 vaginal samples from patients with urogenital uroplasmosis was carried out. U. parvum were detected in 67.3% patients, U. urealyticum--in 12.5% and in 20.1% cases--two species were registered at the same time. Isolation of clinical significant concentration of both ureaplasma (> 10(4) CFU/ ml) was detected in about 50% of cases. Expression of inflammation of vaginal mucus depended on the level of concentration of infection agents. U. parvum were associated with bacterial vaginosis, while in urogenital candidosis U. parvum was detected rarer than U. urealyticum. The dominant numbers of clinical ureaplasma were high sensitive to "new" macrolides and chinolons, however the high percent of isolates were resistant to erytromicin and doxiciclin.     

Purification of urease from Ureaplasma urealyticum

We have purified urease from the Mollicutes, Ureaplasma urealyticum, using high performance liquid chromatography methods and DEAE-Sephadex chromatography. While only small amounts of material could be utilized in these methods, urease was purified at least 180-fold, yield a major band on SDS-PAGE of 66,000 daltons, a minor band of 64,000 daltons, and several faint bands of lower molecular mass. These results suggest that the 380,000 dalton intact urease is a pentamer or hexamer of these two larger subunits. The highly purified urease from DEAE-Sephadex retained full activity for at least 20 days at 4 degrees C in sodium phosphate buffer (pH 7.2) with 1% bovine serum albumin. The estimated specific activity of the DEAE peak fractions, 180 IU/micrograms, is at least 90-fold greater than that of jack bean urease.     

Characteristics of Ureaplasma urealyticum urease.

Sonication of Ureaplasma urealyticum cells grown in a dialysate growth medium effectively separated the cytoplasmic fraction from the membrane fraction, with both fractions relatively free from exogenous contaminating proteins. The urease activity was associated with the cytoplasmic fraction, and the ureaplasmal urease exhibited a specific activity higher than that of crystalline jack bean urease. The enzymatic activity of the ureaplasmal enzyme was optimum at pH 7.5 and was resistant to the chelating agents EDTA and sodium citrate. Sulfhydryl-blocking agents such as HgCl2 and Pb(NO3)2 inhibited the ureaplasmal urease, which was also shown to be particularly sensitive to flurofamide and, to a much lesser extent, to acetohydroxamic acid. Electrophoretic analysis of the proteins of the ureaplasmal cell fractions combined with Western immunoblot with an antiserum to the ureaplasmal urease indicated that the urease constitutes a major component of the cytoplasm and is composed of several 70-kilodalton polypeptides.     

Urea-hydrolysis-dependent citrulline synthesis by Ureaplasma urealyticum

Some of the ammonia produced by hydrolysis of urea by Ureaplasma urealyticum is channelled into an anabolic pathway with resultant 'de novo' synthesis of citrulline. The organism appears to possess ornithine carbamoyltransferase and carbamoyl phosphate synthetase or some modified form of these enzymes.     

Comparative genome analysis of 19 Ureaplasma urealyticum and Ureaplasma parvum strains

ABSTRACT: BACKGROUND: Ureaplasma urealyticum (UUR) and Ureaplasma parvum (UPA) are sexually transmitted bacteria among humans implicated in a variety of disease states including but not limited to: nongonococcal urethritis, infertility, adverse pregnancy outcomes, chorioamnionitis, and bronchopulmonary dysplasia in neonates. There are 10 distinct serotypes of UUR and 4 of UPA. Efforts to determine whether difference in pathogenic potential exists at the ureaplasma serovar level have been hampered by limitations of antibody-based typing methods, multiple cross-reactions and poor discriminating capacity in clinical samples containing two or more serovars. RESULTS: We determined the genome sequences of the American Type Culture Collection (ATCC) type strains of all UUR and UPA serovars as well as four clinical isolates of UUR for which we were not able to determine serovar designation. UPA serovars had 0.750.78 Mbp genomes and UUR serovars were 0.840.95 Mbp. The original classification of ureaplasma isolates into distinct serovars was largely based on differences in the major ureaplasma surface antigen called the multiple banded antigen (MBA) and reactions of human and animal sera to the organisms. Whole genome analysis of the 14 serovars and the 4 clinical isolates showed the mba gene was part of a large superfamily, which is a phase variable gene system, and that some serovars have identical sets of mba genes. Most of the differences among serovars are hypothetical genes, and in general the two species and 14 serovars are extremely similar at the genome level. CONCLUSIONS: Comparative genome analysis suggests UUR is more capable of acquiring genes horizontally, which may contribute to its greater virulence for some conditions. The 4 overwhelming evidence of extensive horizontal gene transfer among these organisms from our previous studies combined with our comparative analysis indicates that 6 ureaplasmas exist as quasispecies rather than as stable serovars in their native environment. Therefore, differential pathogenicity and clinical outcome of a ureaplasmal infection is most likely not on the serovar level, but rather may be due to the presence or absence of potential pathogenicity factors in an individual ureaplasma clinical isolate and/or patient to patient differences in terms of autoimmunity and microbiome.